Meda Pharma Hungary GM Dr. Laszlo Gaspar describes how the strategic shift from Rx to OTC has allowed the company to experience year-on-year growth over the last eight years and increase annual revenues threefold. He further emphasizes the value of targeting medical promotion in securing a competitive positioning in several niche segments, while detailing his ambitions to diversify the business into other areas such as food supplements.
What priorities were at the top of your agenda when becoming general manager and how far has the affiliate grown now, under your leadership?
During the span of my tenure we’ve been able to grow revenues from HUF 800 million (USD 2.8 million) to HUF 2.3 billion (USD 8.1 million).
